Vertex tests shorter Incivek therapy in patient subset

Tools

Vertex Pharmaceuticals ($VRTX) will put its Incivek hepatitis C treatment through a trial to determine whether combination therapy for the disease could be shortened to 12 weeks in patients with a particular genetic variation associated with a stronger and faster response to antiviral therapy. Vertex release